Prot #NU 16G03: An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date10/18/1610/18/22

Funding

  • Merck Sharp & Dohme Corporation (Prot #NU 16G03)